Or­bimed part­ner in search of a cure for Parkin­son’s launch­es new gene ther­a­py play­er

Jonathan Sil­ver­stein is ac­tive­ly look­ing for a biotech mir­a­cle.

The Or­bimed part­ner formed a non­prof­it group called the Sil­ver­stein Foun­da­tion af­ter he was di­ag­nosed with Parkin­son’s, and now he’s launch­ing a new biotech which he hopes can pro­vide just that.

The new biotech is called Pre­vail Ther­a­peu­tics. Based in New York, it will be run by Co­lum­bia Uni­ver­si­ty’s Asa Abe­liovich, look­ing to de­vel­op gene ther­a­pies that will try to cor­rect a dis­ease that has proven to be one of the tough­est tar­gets in drug de­vel­op­ment. Or­bimed and the foun­da­tion — which Sil­ver­stein is al­so fund­ing — are back­ing the start­up along with Re­genXBio, one of the lead­ers in AAV tech used in the gene ther­a­pies now in clin­i­cal de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.